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Background: The incidence of perioperative myocardial infarction (PMI) globally is known to be around 2 to 3%
and can prolong hospitalization, increased morbidity and mortality. Little is known about the pathophysiology and
risk factors for PMI. We investigate the presence of elevated novel cardiac markers and preoperative coronary artery
plaque through contemporary laboratory techniques to determine the correlation with PMI, as well as studying
ivabradine and atorvastatin as protective pharmacotherapies against PMI in the context of orthopedic surgery.
Methods/Design: We aim to enroll 200 patients aged above 60 years who suffer from neck of femur fracture
requiring surgery. Patients will be randomized to four arms (no study drugs, atorvastatin only, ivabradine only and
ivabradine and atorvastatin). Our primary outcome is incidence of PMI. All patients will receive an electrocardiogram,
cardiac echocardiography, measurement of novel cardiac biomarkers and computed tomography (CT) coronary
angiography. A telephone interview post discharge will be conducted at 30 days, 60 days and 1 year.
Discussion: We postulate that ivabradine and atorvastatin will reduce the rate and magnitude of PMI following surgery
by reducing heart rate and attenuating catecholamine-induced tachycardia postoperatively. Secondly, we postulate
that postoperative reduction in heart rate and catecholamine-induced tachycardia with ivabradine will correlate with a
reduction in cardiovascular novel biomarkers which will reduce atrial stretch and postoperative incidence of arrhythmia.
We aim to demonstrate that treatment with ivabradine and atorvastatin will cause a reduction in the incidence and
magnitude of PMI, the benefit of which is derived primarily in patients with greater atherosclerotic burden as measured
by higher CT coronary calcium scores.
Trial registration: This study protocol has been listed in the Australia New Zealand Clinical Trial Registry (registration
number: ACTRN12612000340831) on 23 March 2012.
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In the United States approximately 24 million surgical
procedures are performed annually [1], and it is esti-
mated that 1 million of these operations will be compli-
cated by a perioperative cardiovascular event [2]. With
more than 230 million major surgical operations being
performed every year worldwide, the scope of this prob-
lem is massive [3].
Among patients undergoing major non-cardiac surgery,
the overall incidence of perioperative myocardial infarc-
tion (PMI) is 2 to 3%, and in higher risk populations, such
as those patients undergoing vascular surgery, rates can
be as high as 34% globally [4,5]. PMI is clinically a very
significant occurrence, associated with prolonged hospital
stay, substantial morbidity and mortality rates as high as
25 to 40% [6,7].
The definition of PMI is based on the recent universal
definition and requires a rise and fall of cardiac biomarkers
(preferably troponin), with at least one measurement above
the 99th percentile of the upper reference limit, in the set-
ting of either symptoms of ischemia, electrocardiogram
(ECG) changes or imaging evidence of necrosis [8]. How-
ever, the majority of postoperative troponin elevations
are asymptomatic, without ECG or imaging evidence
of infarction, yet still confer a substantially increased
risk of death [9-11]. As such, the distinction between
infarction and necrosis is often subtle, and many pa-
tients will not meet the criteria for infarction simply
based on the absence of routine postoperative cardiac im-
aging. Furthermore, small myocardial infarcts usually do
not produce wall motion abnormalities on an echocardio-
gram., As such, imaging evidence of small infarcts will rely
on cardiac magnetic resonance imaging [12], a technique
which is often impractical in the postoperative period and
is certainly not routine.
In a previous study of patients undergoing urgent ortho-
pedic surgery, PMI, as defined by troponin I elevation, oc-
curred in 52.9% of patients. The majority of biomarker
elevations in these patients were asymptomatic, with only
9.8% of patients meeting the universal definition criteria
for myocardial infarction. Whilst patients within each
quartile of troponin elevation demonstrated increasing
mortality at 12 months, mortality was dramatically in-
creased across the board in those with any postoperative
troponin elevation (37% versus 2.1%, P <0.0001) [13].
We subsequently performed an intervention study of
patients with troponin elevation following emergent sur-
gery for fractured neck of femur (NOF), and randomized
patients to standard care or referral to the cardiology
unit [14]. The main intervention by the cardiology unit
was commencement of aspirin and beta-blockers, how-
ever this made no difference in mortality at follow-up.
The study did confirm the high rate of troponin eleva-
tion in this group, and again confirmed the increasedmortality conferred by postoperative troponin increase.
It may be that efforts to prevent PMI will be more suc-
cessful in improving outcomes following surgery rather
than postoperative interventions directed at patients
with PMI.
The exact mechanisms of PMI are not well under-
stood, however two broad theories are postulated; myo-
cardial stress and plaque rupture [15]. Prevention of
myocardial stress and/or plaque rupture may reduce the
incidence of PMI and therefore have been the subject of
multiple studies.
Myocardial stress (myocardial oxygen supply-demand
imbalance) and role of ivabradine
Studies suggest that tachycardia is the most common
cause of postoperative oxygen supply-demand imbalance
leading to PMI [16,17]. Numerous studies using peri-
operative Holter monitoring in patients undergoing
major surgery have shown that asymptomatic, heart rate
related ST segment depression is common postopera-
tively and associated with in-hospital [18,19] and long-
term morbidity and mortality [20]. Postoperative cardiac
complications, including sudden death, occur after pro-
longed silent ST segment depression [11,16,21-25]. Fur-
thermore, peak troponin elevation correlates with the
duration of ST segment depression [16].
These studies are the basis for trials examining the use
of perioperative beta-blockers to reduce the incidence of
postoperative cardiac events. Initial small studies were
promising [5,26], however other moderate-sized ran-
domized trials failed to show benefit [27,28]. A subse-
quent meta-analysis of non-cardiac surgery randomized
controlled trials did suggest a benefit for beta-blockers
in the reduction of cardiovascular events, but showed an
increased risk of hypotension and bradycardia [29]. The
largest randomized controlled trial to date, the POISE
trial (Effects of extended-release metoprolol succinate in
patients undergoing non-cardiac surgery), randomized
8,351 patients at increased risk of cardiovascular events to
receive metoprolol or placebo [30]. The group assigned to
metoprolol showed a reduction in myocardial infarction
(4.2 versus 5.7%, P = 0.002), however there was an increase
rate of stroke (1.0 versus 0.5%, P = 0.005) and death (3.1
versus 2.3%, P = 0.03) in the treatment group. Clinically
significant hypotension occurred in 625 patients (15%) in
the metoprolol group. This higher incidence of clinically
significant hypotension has been postulated as the cause
for the occurrence of more strokes and deaths.
Postoperative atrial fibrillation (AF) is common both
after cardiothoracic and non-cardiothoracic surgery [31].
In patients undergoing non-cardiothoracic surgery, the
reported incidence of postoperative AF is as high as 12%
[32], and has not been documented in an emergent
orthopedic surgery group where the incidence may be
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tive AF can be observed throughout the postoperative
course, with a peak on the second postoperative day
[33]. Even though postoperative AF can be self-limiting,
it may be associated with hemodynamic derangements,
postoperative stroke, PMI, ventricular arrhythmias and
heart failure [34,35]. In many reports, development of
postoperative AF is associated with a longer hospital
stay, greater morbidity and mortality and increased costs
[33,36]. The pathophysiology of postoperative AF is not
well understood, however right atrial overdistension and
myocardial stretch in response to catecholamine release
may play a significant role [37].
Ivabradine (Coralan™) is an orally bioavailable, specific
inhibitor of the If current in the sinoatrial node [38]. It is
a pure heart rate lowering agent in patients with sinus
rhythm, but unlike beta-blockers it has no effect on
blood pressure [39,40], myocardial contractility [41], in-
tracardiac conduction or ventricular repolarization [42].
Ivabradine could potentially provide the perioperative
benefits of beta-blockers without the detrimental effects
of hypotension, leading to improved outcomes and re-
duced adverse cardiovascular events in the postoperative
period. A small series case study of 15 patients showed
that ivabradine does attenuate catecholamine induced
tachycardia following cardiac surgery, with positive ef-
fects on cardiac index, stroke volume index and mean
arterial pressure [43]. A small (n = 111) non-randomized
study of ivabradine in patients undergoing carotid
endarterectomy found that ivabradine therapy (n = 33)
reduced PMI compared to patients not receiving any
beta-blockers or ivabradine [44]. No randomized studies
with ivabradine in patients undergoing cardiac or
non-cardiac surgery have been performed to date.
Acute coronary syndromes and role of atorvastatin
An acute coronary syndrome occurs when an unstable
or vulnerable plaque undergoes spontaneous rupture,
fissuring or erosion, leading to acute coronary throm-
bosis, ischemia and infarction. Although it is accepted
that intraplaque inflammation plays a pivotal role in
plaque instability and spontaneous acute coronary syn-
drome [45], external stressors such as those occurring
postoperatively are also believed to contribute [39,40],
especially in patients with vulnerable plaque character-
ized by a thin fibrous cap [18]. Indeed, the majority of
perioperative troponin elevations occur in patients with
underlying coronary artery disease (CAD) [10,11,46,47].
Hormones that increase cardiovascular stress, such cate-
cholamines and cortisol, increase after surgery and may
remain elevated for days [48-50]. Elevation in plasma
catecholamines correlates with postoperative cardiac
troponin elevations [50] and with graft occlusion after
vascular surgery [51]. Whilst myocardial oxygen supply-demand may be the predominant mechanism of injury,
this remains unproven. The cardiovascular tension and
shear stress induced by hemodynamic changes as a re-
sult of catecholamine increase may also induce plaque
rupture or erosion leading to acute coronary thrombosis,
ischemia and infarction. Increased platelet reactivity in
the postoperative period may also be a significant con-
tributor to plaque events leading to PMI [52].
Atorvastatin (40 mg orally daily) administered for seven
days prior to percutaneous coronary intervention (PCI)
reduces the incidence of PMI [53]. It has subsequently
been shown that even a single high dose (80 mg) of ator-
vastatin within 24 hours prior to PCI significantly lowers
the overall incidence of myocardial infarction not limited
only to PMI rate [54].
A retrospective cohort study of 780,591 patients who
underwent major non-cardiac surgery and who received
statin therapy during the first two hospital days showed
a reduction in crude and adjusted mortality in the statin
group [55]. The authors concluded that ‘treatment with
lipid-lowering agents may reduce risk of death following
major non-cardiac surgery. Clinical trials are required to
confirm this observation’. A subsequent review showed
reduced death for statin therapy in cardiac and vascular
surgery, but reported no randomized trials of statin ther-
apy in non-cardiovascular surgery [56].
Novel cardiac biomarkers
Elevated levels of circulating biomarkers related to car-
diac volume, pressure overload and cardiovascular stress
offer insights into subclinical cardiac stress and thus
have the potential to aid in risk stratification and provide
mechanistic data on disease prevention measures [57].
Specifically, B-type natriuretic peptide (BNP; either the
hormone or the aminoterminal fragment of the prohor-
mone (NT-proBNP)) is a counter-regulatory hormone
released predominantly from ventricular myocytes in re-
sponse to ventricular dysfunction, stretching, increased
wall tension and ischemia. Elevated levels of BNP have
been shown to predict mortality and heart failure events
across a broad range of individuals, ranging from the
general population to patients with coronary disease or
heart failure [57-63]. We recently showed that elevated
NT-proBNP levels pre- and postoperatively are inde-
pendent predictors of in-hospital cardiac events and
two-year mortality [64].
Development of newer assays that target more stable
epitopes of hormones or prohormones that are released
in relation to cardiomyocyte and/or vascular stress offers
the potential for more refined risk assessment [65]. Spe-
cifically, atrial natriuretic peptide (ANP) is a vasodilator
and natriuretic that is synthesized in the myocardium in
response to increased wall tension [66]. Adrenomedullin
(ADM) is a potent vasodilator synthesized in the adrenal
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in response to physical stretch and specific cytokines,
with levels in the heart elevated in the setting of pres-
sure and volume overload [67,68]. Endothelin-1 (ET-1)
is a potent vasoconstrictor and profibrotic hormone that
is secreted by vascular endothelial cells, with levels cor-
relating with shear stress and pulmonary artery pressure
[69]. In patients with stable coronary artery disease and
preserved left ventricular ejection fraction, elevated
levels of these novel biomarkers can help identify pa-
tients who are at higher risk of cardiovascular death and
heart failure [65]. Higher levels of these three bio-
markers have been associated with an increased risk of
death and/or heart failure events in patients with estab-
lished heart failure [70-72].
The prohormones of ANP, ADM and ET-1 are re-
leased in equimolar ratios to the vasoactive hormones
but have a longer half-life. The mid-regional (MR) frag-
ments of proANP and proADM are also more stable
in vivo and ex vivo than the amino- or carboxy-terminal
part of the prohormone, thereby minimizing the risk of
underestimation of levels as a result of early degradation of
crucial epitopes at the extreme ends of the molecule [73].
In studies of patients with established heart failure, ele-
vated levels of MR-proANP, MR-proADM and carboxy-
terminal fragment of ET-1 (CT-proET-1) have been
shown to be associated with mortality independently of
clinical variables, and the biomarkers have displayed prog-
nostic and discriminatory value that has compared favor-
ably with BNP and/or NT-proBNP in the heart failure
population [70-72].
Secretory Phospholipase A2
Secretory phospholipase A2 (sPLA2) and lipoprotein-
associated phospholipase A2 (Lp-PLA2) are enzyme bio-
markers of increased cardiovascular risk [74]. In addition,
arachidonic acid release from membrane phospholipids
by PLA2 is a key step in the control of eicosanoid.
sPLA2 and Lp-PLA2 appear to be prospective candi-
dates for inhibition [75]. High-dose atorvastatin signifi-
cantly reduces sPLA2 and Lp-PLA2 mass and activity
after acute coronary syndromes and mitigates the risk of
death associated with sPLA2 mass. Atorvastatin may exert
anti-inflammatory effects on phospholipases that con-
tribute to its therapeutic benefit after acute coronary
syndromes [74].
Lp-PLA2
Lp-PLA2 is a vascular specific marker that is not elevated
in other inflammatory processes [76]. Lp-PLA2 is pro-
duced in atherosclerotic plaque by macrophages, T cells
and mast cells, is highly concentrated in rupture prone le-
sions, and is bound to low-density and high-density lipo-
protein (LDL and HDL) [77]. Statins have been shown todecrease Lp-PLA2 but not to the same extent as their ef-
fect on LDL levels, suggesting the potential for therapies
that can more specifically target Lp-PLA2.
sPLA2
Type IIA sPLA2 is expressed in hepatocytes, macro-
phages, platelets and vascular smooth muscle cells, and its
plasma levels are upregulated by proinflammatory com-
pounds such as interleukin-1, interleukin-6, tumor necro-
sis factor, interferon and oxidized LDL. sPLA2 can also
hydrolyze unmodified phospholipids, in contrast to Lp-
PLA2 [78]. It has been shown that human atherosclerotic
lesions contain extracellular and intracellular sPLA2 (mac-
rophages and smooth muscle cells) [79]. sPLA2 is less vas-
cular specific than Lp-PLA2. sPLA2 correlates with high
sensitivity C Reactive Protein (hs-CRP) levels and is an
acute-phase reactant [76]. Elevated sPLA2 levels predict
coronary heart disease in patients with stable and unstable
angina and normal subjects [80-84].
Assays
sPLA2 and Lp-PLA2 can be measured as mass or activ-
ity. There is some dispute over the best measurement to
use. Most studies have used mass. There are a number
of competing Lp-PLA2 mass assays on the market and
different assays have been utilized in different studies
with varying results reported. The United States Food
and Drug Administration approved a blood test to meas-
ure Lp-PLA2 mass as a marker of cardiovascular disease
(CVD) risk in 2005 (PLAC diaDexus, California, United
States). Correlation between Lp-PLA2 mass and activ-
ity is variable depending on the clinical scenario as
Lp-PLA2 levels are dependent on circulating LDL and
HDL levels.
Coronary plaque burden
Underlying coronary disease is a prerequisite for acute
coronary syndromes. Coronary artery calcification is a
direct sign of atherosclerotic CAD [85,86] and has been
shown to be a strong predictor for risk of cardiovascular
disease or events, including myocardial infarction and/or
cardiac death [87-89]. The amount of coronary calcium
can be quantified non-invasively by using computed
tomography (CT) techniques and calculating the vol-
ume score [90]. The majority of perioperative tropo-
nin elevations occur in patients with underlying CAD
[10,11,46,47]. Conceivably, patients with a higher bur-
den of CAD would derive the most benefit from interven-
tions aimed at reducing PMI.
Methods/Design
This is a prospective, single-centre (Northern Hospital,
Victoria, Australia), open-label, 2x2 factorial, random-
ized controlled trial of ivabradine and atorvastatin in the
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orthopedic surgery for lower limb fracture. The Northern
Hospital Ethics Committee approved this study on 6 July
2012 (reference number HREC P06/12). This study
complies with the Declaration of Helsinki. Informed
consent will be obtained from all participating patients.
Upon signing informed consent, the patient’s data will
be populated as per protocol.
Primary outcome measure
Based on the peak troponin I level postoperative day 1,
2, 3 and 4, the primary outcome measure will be the fre-
quency (binary outcome) and magnitude (continuous
variable) of new myocardial injury following emergent
orthopedic surgery for lower limb fracture. A troponin I
level of less than 0.04 μg/L is considered positive in our
reference laboratory.
Secondary outcome measures
The secondary outcome measures will be as follows:
myocardial infarction according to the universal defin-
ition [8]; death in-hospital, at 30 days and 12 months;
stroke in-hospital, at 30 days and 12 months; markers of
myocardial stress: NT-proBNP (pmol/L), MR-proANP
(pmol/L), MR-proADM (nmol/L) and CT-proET-1
(pmol/L); and markers of plaque burden: sPLA2 and Lp-
PLA2 mass (%) and activity (%). There are also several
outcomes that will be monitored for safety purposes:
symptomatic bradycardia or heart block requiring the
cessation of ivabradine, and liver enzyme elevation more
than three times the upper limits of normal (ALP, GGT,
AST and ALT measured in U/L) requiring the cessation
of atorvastatin.
Study population
The study aims to recruit 200 patients over the age of
60 years admitted to Northern Hospital with fractured
neck of femur who are planned to undergo surgery
within 48 hours.
Inclusion criteria
Patients may be included in the trial if they are over
60 years of age and have a NOF fracture with surgical
treatment planned for within the next 48 hours.
Exclusion criteria
Patients who meet any of the following criteria will be
excluded from the study: 1) current ivabradine use,
current atorvastatin use of 80 mg daily, 3) heart
rate <65 bpm prior to randomization, 4) known liver dis-
ease or liver enzymes more than three times the higher
limit of normal, 5) preoperative troponin elevation, 6) artifi-
cial pacemakers, sick sinus syndrome or complete heart
block, 7) concomitant CYP3A4 inhibitors (ketoconazole,macrolides, cyclosporin, gestodene and antiretrovirals),
8) significant cognitive disorders, and 9) patients who do
not undergo surgical treatment for lower limb fracture for
any reason. If such patients were initially enrolled they will
be excluded from the analysis (per protocol analysis).
Randomization protocol
Patients will be randomized using a computerized block
randomization method with blocks of variable sizes to
ensure ‘true’ randomization and equal numbers in each
treatment group. Patients will be randomized to one of
four groups in a 1:1:1:1 ratio: no treatment (control
group), atorvastatin 80 mg daily, ivabradine twice daily
(as per protocol), or ivabradine twice daily (as per proto-
col) and atorvastatin 80 mg daily.
Ivabradine protocol
Open-label ivabradine will be administered according to
the following protocol.
Heart rate 65 to 90 bpm at randomization: starting
dose of 5.0 mg administered orally twice daily commen-
cing immediately after randomization (within two hours
and prior to surgery) and continued until discharge.
Heart rate >90 bpm at randomization: starting dose of
7.5 mg administered orally twice daily commencing im-
mediately after randomization (within two hours and
prior to surgery) and continued until discharge. ivabra-
dine dose and heart rate will be reviewed on a daily basis
by the cardiology research fellow (associate investigator)
and adjusted as follows: 1) if heart rate remains over
65 bpm during treatment then ivabradine dosage will be
increased by 2.5 mg twice daily to a maximum of 7.5 mg
twice daily; 2) if heart rate falls below 50 bpm during
treatment then ivabradine dosage will be reduced by
2.5 mg twice daily; and finally 3) if heart rate remains
below 50 bpm on ivabradine 2.5 mg twice daily then
ivabradine will be ceased.
Atorvastatin protocol
Open-label atorvastatin will be administered according to
the following protocol. A dosage of 80 mg administered or-
ally daily will commence immediately after randomization
(within two hours and prior to surgery) and will continue
until discharge (unless otherwise indicated according to
history and lipid profile). A liver function test and creatin-
ine kinase levels will be monitored to assess side effects.
Electrocardiography protocol
A digital 12-lead ECG will be recorded preoperatively and
on postoperative days 1, 2 and 3 and assessed for heart
rate, PR interval, QRS duration and morphology, Q waves,
QT duration and QTc, as well as ST-T morphology and
overall interpretation to look for changes that meet the
universal definition of myocardial infarction.
Table 1 Calcium score interpretation
Translation of calcium score
Calcium
score
Implication Risk of coronary artery disease
0 No identifiable plaque Very low, generally less than 5%
1 – 10 Minimal identifiable
plaque
Very unlikely, less than 10%
11 – 100 Definite, at least mild
atherosclerotic plaque
Mild or minimal coronary
narrowings likely
101 – 400 Definite, at least moderate
atherosclerotic plaque
Mild coronary artery disease highly





High likelihood of at least one
significant coronary narrowing
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A transthoracic echocardiogram will be done on every pa-
tient prior to discharge to assess for evidence of regional
wall motion abnormality, systolic and diastolic dysfunction.
Images of the left ventricle in motion and hemodynamic
measures will be recorded at rest.
Holter protocol
Continuous 48-hour Holter monitoring will be com-
menced within 24 hour postoperatively to assess for heart
rate, postoperative arrhythmia including atrial fibrillation,
its frequency and its duration.
CT coronary calcium protocol
A non-invasive, non-contrast CT coronary calcium score
will be acquired on a 320-detector row CT scanner
(Toshiba Aquilion ONE, Toshiba Medical Systems, Ota-
wara, Japan) prior to or at discharge following surgery.
The scan range will be planned between the carina and
cardiac apex. Depending on the expected scan range, a
320 × 0.5 mm or a 280 × 0.5 mm detector configuration
will be used as previously described [91]. Immediately
before image acquisition, an optimal reconstruction
phase will be automatically determined during a breath
hold exercise with ECG-recording by use of cardiac scan-
ning software (SureCardio, Toshiba Medical Systems,
Otawara, Japan). Full cardiac calcium score acquisition will
be performed in a single gantry rotation (0.35 seconds) dur-
ing breath hold at inspiration that allows image reconstruc-
tion at a single cardiac phase. Scan parameters: tube
voltage 120 kV and tube current 200 to 400 mA (dependent
on patient size and shape as visually assessed by the radi-
ology technician: 200 mA for small and/or thin patients,
250 mA for normal patients and 300 to 400 mA for large
and/or obese patients).
Image reconstruction will be performed using a standard
reconstruction kernel filter from the cardiac scanning soft-
ware (SureCardio, Toshiba Medical Systems, Otawara, Japan)
with a 200 to 220 mm2 field of view. Non-overlapping
0.5 mm datasets will be reconstructed for evaluation of
coronary calcium, and the reconstructions transferred to a
post-processing workstation for analysis.
Calcium volume scores (Table 1) will be performed on
a post-processing workstation (Vitrea FX, version 1.0,
Vital Images, Minnetonka, United States), using calcium
score analysis software (VScore, Vital Images). Coronary
calcium will be defined as an area of at least three ‘face-
connected’ voxels in the axial plane in the course of a cor-
onary artery, with an attenuation threshold-value of ≥130
Hounsfield units (HU).
Troponin I
Serum for troponin I measurement will be taken pre-
operatively (within two hours of randomization) and ondays 1, 2, 3 and 4 postoperatively. Serum will be stored
at −70°C. Prior to analysis, the frozen serum will be
thawed, thoroughly mixed and re-centrifuged.
Troponin I will be measured using the Architect STAT
Troponin I assay (Abbott Diagnostics, Abbot Park, IL,
USA). The 99th percentile of a healthy reference popula-
tion using this assay has been previously established at
0.03 mcg/l and levels above this are considered indica-
tive of myocardial injury. The coefficient of variation
(CV) for this assay is 10% at the 99th percentile.
Markers of cardiovascular stress
Levels of MR-proANP, MR-proADM and CT-proET-1
will be determined using the Time-Resolved-Amplified-
Cryptate-Emission (TRACE) technology on the Kryptor
Compact analyzers (BRAHMS GmbH, Henningsdorf,
Germany), from samples collected at the same time
points as troponin.
T-pro-BNP levels will be measured using the Elecsys
electrochemiluminescence immunoassay (ECLIA) proBNP
II assay on a Roche Cobas E170 analyzer (Roche, Indian-
apolis, IN), from samples collected at the same time points
as troponin. This assay uses two polyclonal antibodies that
recognize epitopes located on the N-terminal part of pro-
BNP. The lower limit of the detection range (sensitivity) is
5 pg/ml. Within-run coefficients of variation are 1.9% at a
concentration of 64 pg/ml and 1.3% at 14,142 pg/ml. Total
precision coefficients of variation are 3.1% at a concentra-
tion of 36 pg/ml and 2.7% at 125 pg/ml. Levels of the bio-
markers of the renin-angiotensin pathway, including Ace2,
will be measured.
Markers of plaque burden
Total cholesterol, triglycerides, HDL and LDL will be
measured at randomization (fasting sample just prior to
surgery) and again on day 2 postoperatively (fasting sam-
ple), using the same venipuncture as the preoperative
and day 2 troponin measurement.
sPLA2 and Lp-PLA2 mass and activity assays will
be performed at the same time point as fasting lipids.
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ELISA based assay (sPLA2: Cayman Chemical Co., Ann
Arbor, Michigan, United States and Lp-PLA2: diaDexus
Co. California, United States). sPLA2 activity is measured
by a fluorometric assay. All blood samples will be col-
lected and put on ice prior to centrifugation, separation
and storage at –80°C in a dedicated secure freezer. Batch
testing will then be performed at a later date.
Follow-up protocol
All patients will be followed up on by means of a semi-
structured interview (via telephone call) at 30 days,
6 months and 1 year, enquiring about any cardiac events,
hospitalizations, functional level and medication usage.
Additionally their medical records will be retrieved and/
or primary physician contacted for more information.
Deaths will be confirmed with the Births, Marriages and
Deaths registry.
Sample size calculation
We estimated that 200 patients (calculated sample size
of 171) would be required to have a power of 0.90
(alpha = 0.05, two tail) to identify a difference(moderate
effect size (f = 0.25) in PMI incidence between the 4
groups. (F test Anova:fixed effects,special,main effects
and interactions; Analysis: a priori).
We plan to recruit 200 patients in total (50 in each
treatment cell), providing an actual power of 0.94 to de-
tect a moderate effect size.
Statistical analysis
A comprehensive statistical analysis will be performed
using SPSS (IBM, USA) for the a priori hypotheses.
Baseline characteristics will be reported as mean ± SD for
normally distributed continuous variables, and as counts
(percentages) for categorical variables. The Spearman cor-
relation will be used to calculate the association between
different biomarkers. A Cox proportional-hazards model
will be used to examine the association between bio-
marker levels and outcomes. A value of P <0.05 will be
considered statistically significant.
Discussion
Through this study, we postulate that ivabradine will re-
duce the rate and magnitude of PMI following emergent
lower limb orthopedic surgery by reducing heart rate and
attenuating catecholamine-induced tachycardia postopera-
tively. Secondly, we postulate that postoperative reduction
in heart rate and catecholamine-induced tachycardia with
ivabradine will correlate with a reduction in biomarkers of
cardiovascular stress as measured by NT-proBNP, MR-
proANP, MR-proADM and CT-proET-1, which will reduce
atrial stretch and postoperative incidence of atrial fibrilla-
tion. We further postulate that atorvastatin will reduce therate and magnitude of PMI following emergent lower limb
orthopedic surgery via a reduction in sPLA2 and Lp-PLA2
mass.
To conclude, we aim to demonstrate that treatment
with ivabradine and atorvastatin will cause a reduction
in the incidence and magnitude of PMI, the benefit of
which is derived primarily in patients with greater ath-
erosclerotic burden as measured by higher CT coronary
calcium scores.
Trial status
This study is currently recruiting participants since 2012
and finishes once 200 patients are recruited.
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